Is Semaglutide FDA Approved? Not When Compounded

Is semaglutide FDA approved? Not when compounded. The molecule has branded forms: Ozempic for type 2 diabetes, Rybelsus as an oral type 2 diabetes medicine, and Wegovy for chronic weight management and certain additional indications. Through Promise, semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.

The distinction is product-specific, not a verdict on the molecule. FDA review status is one input, not a marketing gate: a licensed provider may still prescribe a compounded formulation, and that decision belongs to the patient and the doctor.

Is semaglutide FDA approved? Not as a compounded product

Yes for named brands and defined uses; no for a compounded preparation. FDA records place the initial U.S. approvals for Ozempic on December 5, 2017, Rybelsus on September 20, 2019, and Wegovy on June 4, 2021. The current picture as of August 2026 is broader:

The evidence behind those decisions is indication-specific. In STEP 1, published in the New England Journal of Medicine in 2021, 1,961 adults with overweight or obesity but without diabetes had mean weight changes of −14.9% with semaglutide and −2.4% with placebo at 68 weeks (PMID 33567185). In SELECT, published in the New England Journal of Medicine in 2023, a major cardiovascular event occurred in 6.5% of the semaglutide group and 8.0% of the placebo group among 17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes (PMID 37952131); FDA added the cardiovascular indication in March 2024.

For MASH, the 2025 ESSENCE interim analysis found resolution without worsening fibrosis in 62.9% of the semaglutide group and 34.3% of the placebo group; improvement in fibrosis without worsening MASH occurred in 36.8% and 22.4%, respectively (PMID 40305708). FDA used accelerated approval, with a confirmatory outcomes trial continuing. A brand's label does not transfer to a different compounded preparation.

The Wegovy brand continued to change: FDA's December 2025 approval letter covers oral tablets for weight and cardiovascular indications, while the March 2026 decision added Wegovy HD. Semaglutide brand names explains why the same active molecule can sit behind different labels.

What changed when the semaglutide shortage ended

Semaglutide injection products entered FDA's shortage list in 2022. On February 21, 2025, FDA declared the shortage resolved, saying the manufacturer's supply and capacity could meet present and projected national demand. Local supply interruptions could still occur.

FDA then set transition periods for compounding tied to shortage status:

Those dates ended broad shortage-based discretion for essentially copying a marketed semaglutide injection. They did not erase every route to patient-specific compounding. Tirzepatide is a different molecule with its own branded products and regulatory history; a clinician may consider it as an alternative only after comparing the patient's goals, history and contraindications.

What patient-specific 503A compounding can still mean

FDA's April 1, 2026 update says section 503A compounding starts with a prescription for an identified patient. A compounder may not regularly make inordinate amounts that are essentially copies of a commercially available drug. The agency recognizes an exception when the prescriber determines and documents that a change produces a significant difference for that individual patient.

That is narrower than saying any custom prescription automatically qualifies. It also differs from section 503B: as of August 2026, FDA says semaglutide appears on neither the 503B bulks list nor the shortage list. Compounded semaglutide covers the practical differences between a patient-specific preparation and a branded pen.

Route does not settle status either. Rybelsus and Wegovy tablets are branded oral products with their own reviewed labels; a compounded injection is not their generic equivalent. The separate guide to oral semaglutide explains how tablets differ from injections.

Base semaglutide, salt forms and dosing errors

Approval status alone does not make every non-brand product equivalent. A prescription-compounded product should be pharmacy-labeled for an identified patient and traceable to the dispensing pharmacy. Grey-market vials sold as laboratory material can bypass both provider review and pharmacy dispensing.

The active ingredient matters. On its current GLP-1 concerns page, FDA says semaglutide sodium and semaglutide acetate are different active ingredients from the base form used in branded drugs; the agency says it lacks information showing the same chemical and pharmacologic properties and knows of no lawful basis for using those salts in compounding. Promise's prescription route uses base semaglutide, not those salt forms.

Packaging matters too. FDA has linked some reported adverse events to measurement mistakes with multi-dose compounded vials, including confusion among milligrams, milliliters and syringe units. As of May 31, 2026, the agency had received 990 adverse-event reports associated with compounded semaglutide, while cautioning that a report does not establish that the product caused the event. A pharmacy label, a clear prescribed amount and access to the clinical team are practical safeguards against that ambiguity.

What a legitimate prescription route looks like

At Promise, a licensed provider reviews every request and either prescribes when medically appropriate or declines; not everyone qualifies. When a prescription is written, a licensed U.S. compounding pharmacy prepares and labels the medication for that patient. The reviewing provider remains accountable for the clinical decision and follow-up.

That structure is the meaningful line: named product, named patient, prescription, pharmacy label and a clinician who can answer questions. It does not turn the compounded preparation into an approved brand. It does make the route fundamentally different from an anonymous vial offered without clinical review.